Netflix To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Wednesday
Portfolio Pulse from Avi Kapoor
Wall Street analysts have updated their price targets and ratings for several US-listed companies. Keybanc raised Netflix's target to $545, maintaining an Overweight rating. Goldman Sachs increased Twist Bioscience's target to $45 and upgraded it to Buy. Piper Sandler raised Burlington Stores' target to $240 and upgraded to Overweight. UBS increased Visteon's target to $145 and upgraded to Buy. JP Morgan lowered Morgan Stanley's target to $87 and downgraded to Neutral. Rosenblatt raised ANSYS's target to $345 but downgraded to Neutral. Barclays cut SolarEdge's target to $50 and downgraded to Underweight. HC Wainwright raised Apellis Pharmaceuticals' target to $92, maintaining a Buy rating. Telsey Advisory cut Waldencast's target to $12 but kept an Outperform rating. Jefferies slashed Allakos's target to $1.5 and downgraded to Hold.
January 17, 2024 | 1:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright raised Apellis Pharmaceuticals' price target from $82 to $92, maintaining a Buy rating.
The raised price target and maintained Buy rating by HC Wainwright could lead to positive investor sentiment and a potential increase in the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Piper Sandler increased Burlington Stores' price target from $155 to $240 and upgraded the stock to Overweight.
The upgrade to Overweight and raised price target by Piper Sandler could encourage investor confidence, potentially leading to a short-term rise in the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Keybanc raised Netflix's price target from $525 to $545 and maintained an Overweight rating.
The increase in price target and the maintenance of an Overweight rating by Keybanc could lead to a positive short-term sentiment among investors, potentially driving the stock price up.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Goldman Sachs increased Twist Bioscience's price target from $25 to $45 and upgraded the stock to Buy.
The significant increase in price target and upgrade to Buy by Goldman Sachs suggests a strong bullish outlook that may positively influence the stock's short-term performance.
CONFIDENCE 85
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
UBS raised Visteon's price target from $143 to $145 and upgraded the stock to Buy.
UBS's upgrade to Buy and a slight increase in price target may have a positive impact on Visteon's stock price in the short term, especially following a recent gain.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 90
NEUTRAL IMPACT
Rosenblatt raised ANSYS's price target from $332 to $345 but downgraded the stock from Buy to Neutral.
The increase in price target is positive, but the downgrade to Neutral sends mixed signals, likely resulting in a neutral short-term impact on the stock price.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Telsey Advisory cut Waldencast's price target from $13 to $12 but maintained an Outperform rating.
The slight decrease in price target is negative, but the maintenance of an Outperform rating could balance the short-term impact on the stock price.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Jefferies slashed Allakos's price target from $6 to $1.5 and downgraded the stock to Hold.
The drastic reduction in price target and downgrade to Hold by Jefferies could further dampen investor sentiment and negatively impact Allakos's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 90
NEGATIVE IMPACT
JP Morgan lowered Morgan Stanley's price target from $94 to $87 and downgraded the stock to Neutral.
The reduction in price target and downgrade to Neutral by JP Morgan could lead to negative investor sentiment and a potential decrease in the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 85
RELEVANCE 90
NEGATIVE IMPACT
Barclays lowered SolarEdge's price target from $74 to $50 and downgraded the stock to Underweight.
The significant cut in price target and downgrade to Underweight by Barclays could negatively affect SolarEdge's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 85
RELEVANCE 90